Patents by Inventor Xiangrong Dai
Xiangrong Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101619Abstract: A protein with an activity of inhibiting angiogenesis and inflammation, and a specific structure, use, and preparation method thereof are provided. The protein can inhibit both angiogenesis and inflammation, and can prevent and alleviate ophthalmic diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and pterygium to some extent based on a dual action mechanism.Type: ApplicationFiled: January 13, 2021Publication date: March 28, 2024Applicant: ZHAOKE (GUANGZHOU) OPHTHALMOLOGY PHARMACEUTICAL LTD.Inventors: Xiaoyi LI, Xiangrong DAI, Li FANG, Fang QIAN, Yinping YAN, Zicheng DAI, Luoyi LI
-
Publication number: 20230346644Abstract: A medicine bottle for separately containing, preparing, and delivering solid and liquid medicine includes a bottle body, a first sealing separator, a second sealing separator, a sliding penetration rod, and a protective structure. The first sealing separator and the second sealing separator are separately sealed and arranged inside the bottle body to separate a compartment of the bottle body into upper, middle, and lower chambers. The sliding penetration rod is arranged inside the upper chamber of the bottle body as a cylinder in clearance fit with an inner wall of the bottle body, forming piston-like connection allowing for relative sliding. The sliding penetration rod has a through hole inside and a length greater than a sum of lengths of the upper and lower chambers of the bottle body. The protective structure is cup-shaped and fastened upside-down on a top of the bottle body to protect the sliding penetration rod.Type: ApplicationFiled: December 19, 2019Publication date: November 2, 2023Applicant: ZHAOKE (GUANGZHOU) OPHTHALMOLOGY PHARMACEUTICAL LIMITEDInventors: Xiangrong DAI, Xiaoyi LI, Lei YIN, Yifan DU
-
Publication number: 20220370550Abstract: A method of preparing a medicament for inhibiting an inflammation includes the step of using an antiplatelet thrombolysin. The antiplatelet thrombolysin consists of two peptide chains of ? chain and ? chain, and the ? chain amino acid sequence is shown in SEQ ID NO:1, ? chain the amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1, or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2; and the antiplatelet thrombolysin has an activity of inhibiting the inflammation.Type: ApplicationFiled: March 29, 2019Publication date: November 24, 2022Applicant: ZHAOKE PHARMACEUTICAL (HEFEI) COMPANY LIMITEDInventors: Jaehyung CHO, Xiaoyi LI, Xiangrong DAI
-
Publication number: 20220370572Abstract: A method of preparing a medicament for a treatment of anemia includes the step of using an antiplatelet thrombolysin in preparing the medicament, and the antiplatelet thrombolysin has an activity of improving the anemia. The antiplatelet thrombolysin consists of two peptide chains of ? chain and ? chain, in which the ? chain amino acid sequence is shown in SEQ ID NO: 1, the ? chain amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2.Type: ApplicationFiled: March 29, 2019Publication date: November 24, 2022Applicant: ZHAOKE PHARMACEUTICAL (HEFEI) COMPANY LIMITEDInventors: Jaehyung CHO, Xiaoyi LI, Xiangrong DAI
-
Patent number: 11485978Abstract: Provided are recombinant plasmids containing the gene of the heterodimeric snake venom protein Agkisacutacin A chain and Agkisacutacin B chain, cell strains containing the recombinant plasmids, and a method for expressing the heterodimeric snake venom protein Agkisacutacin. The expression level of Agkisacutacin in the present method exceeds 10 mg/L, and the purity level can reach more than 95% by means of two steps of purification.Type: GrantFiled: November 1, 2016Date of Patent: November 1, 2022Assignee: Zhaoke Pharmaceutical (HEFEI) Company LimitedInventors: Xiangrong Dai, Xiaoyi Li, Fang Qian
-
Patent number: 11241381Abstract: A treatment process of cyclosporine eye gel, comprising the steps of: adding carbomer to water, stirring thoroughly and homogenizing; after the prepared carbomer base swollen, stirring and homogenizing; cooling the carbomer base after moist heat sterilization, performing vacuum degassing, adjusting the pH of the base to 5.0-9.0 with filtered sodium hydroxide solution; mixing polyoxyl 35 castor oil, cyclosporin A raw material, 1,2-propanediol and water in a suitable ratio, preparing into a clear solution under a water bath at 35 to 45° C., and filtering; mixing the filtrate uniformly with the carbomer base, performing vacuum degassing; performing aseptic filling after another filtration. For the process of the present invention, sterilization and filtration is performed before adding carbomer, which is convenient for industrial production.Type: GrantFiled: December 25, 2018Date of Patent: February 8, 2022Assignee: ZHAOKE (GUANGZHOU) OPHTHALMIC DRUG COMPANY LIMITEDInventors: Gang Li, Kailei Cao, Xiaoyi Li, Xiangrong Dai, Lei Yin, Juan Ling
-
Patent number: 11058636Abstract: A dispersion process of adapalene gel preparation, including the following steps: pulverizing adapalene raw material to D50 not more than 10 ?m and D90 not more than 30 ?m by dry detection; adding methyl p-hydroxybenzoate, 1,2-propanediol, carbomer 980 and disodium edetate in water, heating and stirring consistently to obtain a matrix in a uniform jelly; adding poloxamer 188, propylene glycol and ethylene glycol phenyl ether in water, stirring and heating to prepare a mixed solution; adding adapalene in the mixed solution prepared, emulsifying at a high speed, then adding to the matrix for thorough stirring; and then adding a triethanolamine aqueous solution for homogenization and stirring. The preparation prepared has good emulsifying and dispersing effect of adapalene, can be expanded on a large scale, and the industrial promotion prospect is good.Type: GrantFiled: December 21, 2018Date of Patent: July 13, 2021Assignee: ZHAOKE (GUANGZHOU) OPHTHALMIC DRUG COMPANY LIMITEDInventors: Jing Liu, Gang Li, Xiaoyi Li, Xiangrong Dai, Lei Yin, Juan Ling
-
Patent number: 11046723Abstract: The invention provides a process of controlling the impurities of clindamycin hydrochloride, comprising a step of purifying said clindamycin hydrochloride by two-phase high performance liquid chromatography, wherein the chromatographic conditions are as follows: the detection wavelength is 200-220 nm; the column temperature is 20-40° C.; the flow rate is 0.8-1 ml/min; Mobile phase A: 0.025 mol/L potassium dihydrogen phosphate solution; Mobile phase B: Acetonitrile; and gradient elution is performed. The method of controlling impurities of the invention can solve the problem of the interference by excipients and the problem of the separation of many impurities at the same time. It also provides an effective method for setting quality standard of impurities in such a formulation.Type: GrantFiled: December 14, 2018Date of Patent: June 29, 2021Assignee: ZHAOKE (GUANGZHOU) Ophthalmic Drug Company LimitedInventors: Dongsheng Ni, Jing Liu, Gang Li, Xiangrong Dai, Xiaoyi Li
-
Publication number: 20200048644Abstract: Provided are recombinant plasmids containing the heterodimeric snake venom protein Agkisacutacin A chain gene and Agkisacutacin B chain gene, respectively, cell strains containing the recombinant plasmids, and a method for expressing the heterodimeric snake venom protein Agkisacutacin. The expression level of Agkisacutacin in the present method exceeds 10 mg/L, and the purity level can reach more than 95% by means of two steps of purification.Type: ApplicationFiled: November 1, 2016Publication date: February 13, 2020Inventors: Xiangrong Dai, Xiaoyi Li, Fang Qian
-
Publication number: 20190192426Abstract: A treatment process of cyclosporine eye gel, comprising the steps of: adding carbomer to water, stirring thoroughly and homogenizing; after the prepared carbomer base swollen, stirring and homogenizing; cooling the carbomer base after moist heat sterilization, performing vacuum degassing, adjusting the pH of the base to 5.0-9.0 with filtered sodium hydroxide solution; mixing polyoxyl 35 castor oil, cyclosporin A raw material, 1,2-propanediol and water in a suitable ratio, preparing into a clear solution under a water bath at 35 to 45° C., and filtering; mixing the filtrate uniformly with the carbomer base, performing vacuum degassing; performing aseptic filling after another filtration. For the process of the present invention, sterilization and filtration is performed before adding carbomer, which is convenient for industrial production.Type: ApplicationFiled: December 25, 2018Publication date: June 27, 2019Applicant: ZHAOKE (GUANGZHOU) OPHTHALMIC DRUG COMPANY LIMITEDInventors: Gang Li, Kailei Cao, Xiaoyi Li, Xiangrong Dai, Lei Yin, Juan Ling
-
Publication number: 20190192431Abstract: A dispersion process of adapalene gel preparation, including the following steps: pulverizing adapalene raw material to D50 not more than 10 ?m and D90 not more than 30 ?m by dry detection; adding methyl p-hydroxybenzoate, 1,2-propanediol, carbomer 980 and disodium edetate in water, heating and stirring consistently to obtain a matrix in a uniform jelly; adding poloxamer 188, propylene glycol and ethylene glycol phenyl ether in water, stirring and heating to prepare a mixed solution; adding adapalene in the mixed solution prepared, emulsifying at a high speed, then adding to the matrix for thorough stirring; and then adding a triethanolamine aqueous solution for homogenization and stirring. The preparation prepared has good emulsifying and dispersing effect of adapalene, can be expanded on a large scale, and the industrial promotion prospect is good.Type: ApplicationFiled: December 21, 2018Publication date: June 27, 2019Applicant: ZHAOKE (GUANGZHOU) OPHTHALMIC DRUG COMPANY LIMITEDInventors: Jing Liu, Gang Li, Xiaoyi Li, Xiangrong Dai, Lei Yin, Juan Ling
-
Publication number: 20190194258Abstract: A method of controlling the impurities in a cyclosporin A eye gel. A high performance liquid chromatography is performed, and chromatographic conditions are as follows: the detection wavelength is 210-230 nm; the column temperature is 60-68° C.; the flow rate is 0.8-1 ml/min; and the mobile phase A is: THF-water-phosphoric acid. The method of controlling impurities solves the problem of excipients interference and separation of many impurities at the same time, it also provides an effective method for the formulation of quality standard of impurities in this kind of preparation.Type: ApplicationFiled: December 21, 2018Publication date: June 27, 2019Applicant: ZHAOKE (GUANGZHOU) OPHTHALMIC DRUG COMPANY LIMITEDInventors: Gang Li, Kailei Cao, Xiaoyi Li, Xiangrong Dai, Lei Yin, Juan Ling
-
Publication number: 20190185505Abstract: The invention provides a process of controlling the impurities of clindamycin hydrochloride, comprising a step of purifying said clindamycin hydrochloride by two-phase high performance liquid chromatography, wherein the chromatographic conditions are as follows: the detection wavelength is 200-220 nm; the column temperature is 20-40° C.; the flow rate is 0.8-1 ml/min; Mobile phase A: 0.025 mol/L potassium dihydrogen phosphate solution; Mobile phase B: Acetonitrile; and gradient elution is performed. The method of controlling impurities of the invention can solve the problem of the interference by excipients and the problem of the separation of many impurities at the same time. It also provides an effective method for setting quality standard of impurities in such a formulation.Type: ApplicationFiled: December 14, 2018Publication date: June 20, 2019Inventors: Dongsheng Ni, Jing Liu, Gang Li, Xiangrong Dai, Xiaoyi Li
-
Publication number: 20190125843Abstract: A method and pharmceutical compositon for the treatment of thrombotic thrombocytopenic purpura. The method and pharmceutical compositon uses a therapuetically effective amount of an antiplatelet thrombolysin comprising two polypeptide chains, an alpha chain and a beta chain. The antiplatelet thrombolysin of the invention can limit platelet adhesion and aggregation, restore platelets, red blood cell and hemoglobin levels, at the same time, reduce the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocyte hemolytic anemia, so as to achieve the purpose of the treatment of TTP, which has a good prospect of clinical use.Type: ApplicationFiled: April 22, 2016Publication date: May 2, 2019Applicant: Zhaoke Pharmaceutical (HEFEI) Company LimitedInventors: Xiaoyi Li, Xiangrong Dai
-
Publication number: 20150164875Abstract: The present invention relates to the medical field, discloses a compound preparation of lercanidipine hydrochloride and atorvastatin calcium, which has a drug content per unit dosage of 5-20 mg of lercanidipine hydrochloride and 10-80 mg of atorvastatin calcium. The present invention also particularly provides a compound preparation in the form of tablets, which comprises lercanidipine hydrochloride and atorvastatin calcium as main drugs, and calcium carbonate, microcrystalline cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, polysorbate 80, magnesium stearate, pregelatinized starch and colloidal silicon dioxide as auxiliary materials, and opadry as a coating.Type: ApplicationFiled: February 25, 2013Publication date: June 18, 2015Applicant: ZHAOKE PHARMACEUTICAL (GUANGZHOU) COMPANY LIMITEDInventors: Xiaoyi Li, Guohui Zhang, Xiangrong Dai, Juan Ling, Daidi Hu
-
Publication number: 20150079183Abstract: A lercanidipine hydrochloride and losartan potassium compound preparation. In terms of mass percentage, said compound preparation contains 0.5-40% lercanidipine hydrochloride and 6.25-50% losartan potassium. Also provided is a compound preparation which utilizes lercanidipine hydrochloride and losartan potassium as the main ingredient, lactose monohydrate, microcrystalline cellulose, A-type sodium starch glycolate, povidone K30, magnesium stearate, pregelatinized starch and colloidal silicon dioxide as excipients, and opadry white as a coating in the preparation of a tablet. Clinical tests show that compared with single-component preparations, said compound preparation markedly increases the effectiveness of treatment of light and moderate hypertension, markedly reduces the incidence of adverse effects, is tolerated well by patients, and has excellent clinical application prospects.Type: ApplicationFiled: February 25, 2013Publication date: March 19, 2015Inventors: Xiaoyi Li, Guohui Zhang, Xiangrong Dai, Juan Ling, Yan Wu